Can Ativan Be Given Subcutaneously?
Yes, lorazepam (Ativan) can be administered subcutaneously, particularly in palliative care and hospice settings when oral administration is not feasible, though this is an off-label use not approved by the FDA.
FDA-Approved Routes vs. Off-Label Practice
The FDA-approved labeling for Ativan specifies only oral administration 1. The official prescribing information makes no mention of subcutaneous, intramuscular, or any parenteral routes for the oral formulation. However, clinical practice in palliative care has established subcutaneous administration as a viable alternative route.
Evidence for Subcutaneous Use
Palliative Care Context
Subcutaneous administration of benzodiazepines, including lorazepam, is an established practice in hospice and palliative care settings 2. A 2022 scoping review examining off-label subcutaneous drug use in palliative care identified this as a common practice, though it noted that evidence on tolerability and effectiveness remains limited, with pharmacokinetic data particularly sparse 2.
Clinical Precedent from Related Benzodiazepines
While direct evidence for lorazepam is limited, subcutaneous midazolam (a related benzodiazepine) has been well-studied in palliative care. A 1990 study demonstrated that subcutaneous midazolam infusion effectively controlled terminal restlessness and agitation in 22 of 23 cancer patients, with good tolerability at injection sites 3. This establishes proof-of-concept for subcutaneous benzodiazepine administration.
Guideline Support for Lorazepam in Specific Populations
The 2013 KASL guidelines for alcoholic liver disease specifically recommend lorazepam for patients with severe alcohol withdrawal syndrome, advanced age, liver failure, or respiratory failure, noting it can be given via PO/IV/IM routes at 1-4 mg every 4-8 hours 4. While subcutaneous is not explicitly mentioned, the inclusion of IM administration suggests parenteral routes are clinically acceptable.
Practical Considerations
When to Consider Subcutaneous Administration
Subcutaneous lorazepam may be appropriate when:
- Oral route is unavailable (dysphagia, altered consciousness, nausea/vomiting)
- IV access is difficult or unavailable
- Patient is in hospice/palliative care setting
- Terminal agitation or anxiety requires sustained control
Contraindications to Subcutaneous Route
Based on morphine guidelines (which apply broadly to subcutaneous drug administration), avoid subcutaneous lorazepam in patients with 5, 6:
- Generalized edema
- Erythema, soreness, or history of sterile abscesses at injection sites
- Coagulation disorders
- Poor peripheral circulation
Dosing Considerations
The FDA-approved oral dosing is 2-6 mg/day in divided doses, with 1-2 mg/day for elderly patients 1. When converting to subcutaneous administration, start conservatively as bioavailability may differ from oral (90% oral bioavailability) 1. There is no established conversion ratio for lorazepam specifically.
Important Caveats
Off-Label Status
This is off-label use with limited published pharmacokinetic data 2. Documentation of rationale and informed consent (when possible) is essential.
Sedation Risk
Lorazepam causes sedation as a primary effect. Real-world pharmacovigilance data shows sopor, delirium, and psychotic disorder among common adverse events 7. When given subcutaneously in palliative settings, monitor for excessive sedation, though this may be therapeutically desired in terminal agitation.
Absorption Variability
Subcutaneous absorption is generally slower and more sustained than IV administration 8. The abdomen provides most rapid absorption, followed by upper arm, then thigh/hip/buttock 8.
Clinical Bottom Line
Subcutaneous lorazepam is a reasonable off-label option in palliative care when oral administration is impossible and IV access is impractical, based on established practice patterns and extrapolation from related benzodiazepines. However, prescribers must document the clinical rationale, acknowledge the off-label nature, start with conservative doses, and monitor closely for both efficacy and adverse effects. The lack of FDA approval and limited pharmacokinetic data necessitates careful patient selection and monitoring.